Shr-1316
Shr-1316 is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
235 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 8 | — | 1 | — | 9 |
| Adenocarcinoma | D000230 | — | — | — | 6 | 1 | 1 | — | 8 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 7 | 35 | 4 | — | 2 | 41 |
| Lung neoplasms | D008175 | — | C34.90 | 11 | 28 | 4 | — | 5 | 40 |
| Small cell lung carcinoma | D055752 | — | — | 7 | 22 | 5 | — | 6 | 36 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 24 | 1 | — | 1 | 26 |
| Non-small-cell lung carcinoma | D002289 | — | — | 10 | 18 | 2 | — | 1 | 24 |
| Squamous cell carcinoma | D002294 | — | — | 3 | 18 | 1 | — | 1 | 20 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 1 | 15 | 1 | — | 1 | 17 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 3 | 13 | 1 | — | 1 | 15 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | 10 | 1 | — | — | 11 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 9 | 1 | — | — | 10 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 22 | 14 | — | — | 1 | 29 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 8 | — | — | 2 | 10 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 9 | — | — | — | 10 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | 8 | — | — | — | 8 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 2 | 7 | — | — | — | 7 |
| Recurrence | D012008 | — | — | 1 | 5 | — | — | — | 5 |
| Immunotherapy | D007167 | — | — | — | 4 | — | — | — | 4 |
| Rectal neoplasms | D012004 | — | — | — | 3 | — | — | — | 3 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 2 | — | — | — | 2 |
| Uterine cervical neoplasms | D002583 | — | — | — | 2 | — | — | — | 2 |
Show 29 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
| Osteosarcoma | D012516 | — | — | 1 | — | — | — | — | 1 |
| Histiocytosis | D015614 | HP_0100727 | — | 1 | — | — | — | — | 1 |
| Langerhans-cell histiocytosis | D006646 | — | C96.6 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Shr-1316 |
| INN | adebrelimab |
| Description | Shr-1316 is an unknown pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297828 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 1XBY50W1OX (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use